Viatris Inc. or Bio-Techne Corporation: Who Leads in Yearly Revenue?

Viatris vs. Bio-Techne: A Decade of Revenue Growth

__timestampBio-Techne CorporationViatris Inc.
Wednesday, January 1, 20143577630007719600000
Thursday, January 1, 20154522460009429300000
Friday, January 1, 201649902300011076900000
Sunday, January 1, 201756300300011907700000
Monday, January 1, 201864299300011433900000
Tuesday, January 1, 201971400600011500500000
Wednesday, January 1, 202073869100011946000000
Friday, January 1, 202193103200017886300000
Saturday, January 1, 2022110559900016262700000
Sunday, January 1, 2023113670200015426900000
Monday, January 1, 20241159060000
Loading chart...

Unleashing the power of data

Viatris Inc. vs. Bio-Techne Corporation: A Revenue Showdown

In the competitive landscape of biotechnology and pharmaceuticals, Viatris Inc. and Bio-Techne Corporation have emerged as key players. Over the past decade, Viatris has consistently outpaced Bio-Techne in terms of revenue, boasting figures that are approximately 15 times higher on average. From 2014 to 2023, Viatris saw a remarkable growth trajectory, peaking in 2021 with a revenue surge of nearly 80% compared to 2014. Meanwhile, Bio-Techne has shown steady growth, with its revenue increasing by over 220% during the same period. However, the data for 2024 is incomplete, leaving room for speculation on future trends. As the industry evolves, these companies continue to innovate and expand, making them ones to watch in the coming years.

The Future of Biotech Revenue

With Viatris leading the charge, the biotech sector is poised for exciting developments.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025